We are live on ! Find out more

1,781 hedge funds and large institutions have $145B invested in Pfizer in 2014 Q1 according to their latest regulatory filings, with 117 funds opening new positions, 733 increasing their positions, 747 reducing their positions, and 55 closing their positions.

New
Increased
Maintained
Reduced
Closed

113% more first-time investments, than exits

New positions opened: 117 | Existing positions closed: 55

110% more call options, than puts

Call options by funds: $1.89B | Put options by funds: $900M

10% more funds holding in top 10

Funds holding in top 10: 250274 (+24)

3% more funds holding

Funds holding: 1,7371,781 (+44)

5% more capital invested

Capital invested by funds: $138B → $145B (+$6.46B)

0.72% more ownership

Funds ownership: 73.18%73.9% (+0.72%)

2% less repeat investments, than reductions

Existing positions increased: 733 | Existing positions reduced: 747

Holders
1,781
Holders Change
+44
Holders Change %
+2.53%
% of All Funds
51.41%
Holding in Top 10
274
Holding in Top 10 Change
+24
Holding in Top 10 Change %
+9.6%
% of All Funds
7.91%
New
117
Increased
733
Reduced
747
Closed
55
Calls
$1.89B
Puts
$900M
Net Calls
+$990M
Net Calls Change
+$946M
Name Holding Trade Value Shares
Change
Change in
Stake
HIMCH
251
Hartford Investment Management Co (HIMCO)
Connecticut
$57.5M -$2.32M -77,850 -4%
GH
252
GAM Holding
Switzerland
$57.4M -$3.82M -127,989 -6%
AAMU
253
AEGON Asset Management (UK)
United Kingdom
$55.8M -$8.1M -271,754 -13%
MAMU
254
Marathon Asset Management (UK)
United Kingdom
$55.8M +$8.16M +273,682 +18%
OCAM
255
Onex Canada Asset Management
Ontario, Canada
$55.5M +$5.74M +192,386 +12%
IRF
256
IBM Retirement Fund
New York
$55.3M -$29.9M -1,003,323 -36%
First Manhattan
257
First Manhattan
New York
$54.4M +$234K +7,848 +0.4%
HCM
258
Highbridge Capital Management
New York
$54.2M +$1.25M +41,773 +2%
EIM
259
ExxonMobil Investment Management
Texas
$53.7M -$486K -16,286 -0.9%
MIP
260
Mondrian Investment Partners
United Kingdom
$53.2M -$27.8M -933,117 -35%
ZIM
261
Zacks Investment Management
Illinois
$52.8M +$5.79M +194,206 +13%
FIM
262
Foresters Investment Management
New York
$52.2M +$31.4K +1,054 +0.1%
USSCPF
263
United States Steel & Carnegie Pension Fund
New York
$51.8M
MIH
264
Madison Investment Holdings
Wisconsin
$51.4M -$798K -26,761 -2%
CPSAC
265
Chas P. Smith & Associates (CPS)
Florida
$49.3M +$969K +32,497 +2%
TAM
266
Todd Asset Management
Kentucky
$49.1M +$1.1M +36,814 +2%
OTPPB
267
Ontario Teachers' Pension Plan Board
Ontario, Canada
$48.9M -$7.93M -265,977 -14%
Commonwealth Equity Services
268
Commonwealth Equity Services
Massachusetts
$48.7M +$2.87M +96,141 +6%
MA
269
MUFG Americas
New York
$48.2M -$1.51M -50,613 -3%
WCM
270
Wedge Capital Management
North Carolina
$48.2M +$3.27M +109,643 +7%
ProShare Advisors
271
ProShare Advisors
Maryland
$47.6M +$2.52M +84,362 +6%
CIBC Private Wealth Group
272
CIBC Private Wealth Group
Georgia
$47.1M +$45.9M +1,538,134 New
STC
273
SEI Trust Company
Pennsylvania
$45.6M +$398K +13,361 +0.9%
OI
274
Oakbrook Investments
Illinois
$44.9M -$11.5M -386,506 -21%
MC
275
Martin Currie
United Kingdom
$44.1M -$2.12M -71,251 -5%

PFE Hedge Fund Activity: Q1 2014 in Review

1,781 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q1 2014, worth a combined $145B — up 4.7% from $138B a quarter earlier.

Buyers outnumbered sellers: 117 funds opened new PFE positions and 55 closed out — a net gain of 62 holders — while 733 added to existing stakes and 747 trimmed.

The largest buyer was BlackRock Fund Advisors, adding an estimated $301M. The largest seller was Grantham, Mayo, Van Otterloo & Co (GMO), cutting an estimated $630M.

  • 1,781 institutional investors held Pfizer (PFE) as of Q1 2014, up from 1,737 in Q4 2013.
  • Funds reported $145B of Pfizer stock for Q1 2014, up 4.7% quarter-over-quarter.
  • 117 funds opened new Pfizer positions in Q1 2014 and 55 closed out, a net change of +62 holders.
  • The largest Pfizer buyer in Q1 2014 was BlackRock Fund Advisors, an estimated $301M added.
  • The largest Pfizer seller in Q1 2014 was Grantham, Mayo, Van Otterloo & Co (GMO), an estimated $630M sold.

Based on aggregated 13F filings for Q1 2014.